

Xavier Montalban

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2441763/xavier-montalban-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

437
papers

36,431
citations

76
h-index

184
g-index

488
ext. papers

44,518
ext. citations

8.6
avg, IF

6.89
L-index

#	Paper	IF	Citations
437	Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre.. <i>Journal of Neurology</i> , 2022 , 269, 1764	5.5	0
436	Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022 , 9,	9.1	3
435	Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103385	4	1
434	Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 57, 103389	4	1
433	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061343	5	2
432	Body mass index as a predictor of MS activity and progression among participants in BENEFIT.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061861	5	1
431	T1/T2-weighted ratio in multiple sclerosis: A longitudinal study with clinical associations.. <i>NeuroImage: Clinical</i> , 2022 , 34, 102967	5.3	0
430	COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab.. <i>Neurology and Therapy</i> , 2022 , 1	4.6	2
429	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221078825	5	1
428	Spinal cord grey matter atrophy in Multiple Sclerosis clinical practice. <i>Neuroscience Informatics</i> , 2022 , 100071		0
427	Is humoral and cellular response to SARS-CoV-2 vaccine modified by DMT in patients with multiple sclerosis and other autoimmune diseases?. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585221089540	5	1
426	Inflammation in multiple sclerosis induces a specific reactive astrocyte state driving non-cell-autonomous neuronal damage.. <i>Clinical and Translational Medicine</i> , 2022 , 12, e837	5.7	0
425	Genomic Multiple Sclerosis Risk Variants Modulate the Expression of the - Gene Region in Immature Dendritic Cells.. <i>Frontiers in Immunology</i> , 2021 , 12, 816930	8.4	0
424	Optic Nerve Topography in Multiple Sclerosis Diagnosis: The Utility of Visual Evoked Potentials. <i>Neurology</i> , 2021 , 96, e482-e490	6.5	6
423	Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211053001	5	0
422	Assessment of automatic decision-support systems for detecting active T2 lesions in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061339	5	0
421	Charting a global research strategy for progressive MS-An international progressive MS Alliance proposal. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211059766	5	1

420	Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211044479	5	6
419	Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alectuzumab. <i>Frontiers in Immunology</i> , 2021 , 12, 760546	8.4	0
418	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome: A MAGNIMS Study. <i>Neurology</i> , 2021 ,	6.5	4
417	Adding brain volume measures into response criteria in multiple sclerosis: the R \bar{B} -4 score. <i>Neuroradiology</i> , 2021 , 63, 1031-1041	3.2	0
416	Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1455-1457	5	0
415	Menopause does not modify disability trajectories in a longitudinal cohort of women with clinically isolated syndrome and multiple sclerosis followed from disease onset. <i>European Journal of Neurology</i> , 2021 ,	6	3
414	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective: A Review. <i>JAMA Neurology</i> , 2021 , 78, 351-364	17.2	11
413	Selected Clostridia Strains from The Human Microbiota and their Metabolite, Butyrate, Improve Experimental Autoimmune Encephalomyelitis. <i>Neurotherapeutics</i> , 2021 , 18, 920-937	6.4	3
412	Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
411	Scoring the 10-year risk of ambulatory disability in multiple sclerosis: the RoAD score. <i>European Journal of Neurology</i> , 2021 , 28, 2533-2542	6	3
410	CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211010082	5	2
409	Artificial intelligence extension of the OSCAR-IB criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 1528-1542	5.3	3
408	Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. <i>JAMA Neurology</i> , 2021 , 78, 558-567	17.2	39
407	Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry. <i>European Journal of Neurology</i> , 2021 ,	6	6
406	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 51, 102844	4	3
405	A smartphone sensor-based digital outcome assessment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211028561	5	9
404	Targeting Inflammasomes to Treat Neurological Diseases. <i>Annals of Neurology</i> , 2021 , 90, 177-188	9.4	7
403	The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 479-482	5	2

402	Role of B Cells in Multiple Sclerosis and Related Disorders. <i>Annals of Neurology</i> , 2021 , 89, 13-23	9.4	38
401	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102673	4	3
400	Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
399	COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. <i>European Journal of Neurology</i> , 2021 , 28, 3384-3395	6	60
398	U-turn speed is a valid and reliable smartphone-based measure of multiple sclerosis-related gait and balance impairment. <i>Gait and Posture</i> , 2021 , 84, 120-126	2.6	6
397	Differential item functioning of the Arm function in Multiple Sclerosis Questionnaire (AMSQ) by language, a study in six countries. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 90-96	5	4
396	CSF SERPINA3 Levels Are Elevated in Patients With Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	5
395	The frequency and characteristics of MS misdiagnosis in patients referred to the multiple sclerosis centre of Catalonia. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 913-921	5	7
394	Multiple sclerosis is associated with higher comorbidity and health care resource use: A population-based, case-control study in a western Mediterranean region. <i>European Journal of Neurology</i> , 2021 , 28, 4124-4134	6	1
393	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211032803	5	3
392	2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology, The</i> , 2021 , 20, 653-670	24.1	44
391	Immunosenescence in multiple sclerosis: the identification of new therapeutic targets. <i>Autoimmunity Reviews</i> , 2021 , 20, 102893	13.6	14
390	CSF Chitinase 3-Like 2 Is Associated With Long-term Disability Progression in Patients With Progressive Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	2
389	Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated Syndrome. <i>Neurology</i> , 2021 , 97, e1641-e1652	6.5	6
388	Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis. <i>Neurology</i> , 2021 , 97, e1546-e1559	6.5	14
387	Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2021 , 20, 729-738	24.1	19
386	Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patients. <i>Journal of Neurology</i> , 2021 , 1	5.5	3
385	Immunomodulatory Effects Associated with Cladribine Treatment.. <i>Cells</i> , 2021 , 10,	7.9	1

384	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061335		
383	Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102572	4	13
382	Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 461-463	4.4	6
381	Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations. <i>Canadian Journal of Neurological Sciences</i> , 2020 , 47, 437-455	1	18
380	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
379	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14
378	Radiologically Isolated Syndrome: 10-Year Risk Estimate of a Clinical Event. <i>Annals of Neurology</i> , 2020 , 88, 407-417	9.4	35
377	Keeping standards of multiple sclerosis care through the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1153-1156	5	13
376	Targeted resequencing reveals rare variants enrichment in multiple sclerosis susceptibility genes. <i>Human Mutation</i> , 2020 , 41, 1308-1320	4.7	0
375	Optical coherence tomography measures correlate with brain and spinal cord atrophy and multiple sclerosis disease-related disability. <i>European Journal of Neurology</i> , 2020 , 27, 2225-2232	6	6
374	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420935019	6.6	10
373	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020 , 95, e1027-e1040	6.5	11
372	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020 , 41, 1647-1650	3.5	31
371	Hemophagocytic syndrome following alemtuzumab treatment for multiple sclerosis: A case report. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101973	4	1
370	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. <i>Nature Reviews Neurology</i> , 2020 , 16, 171-182	15	68
369	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , 2020 , 19, 234-246	24.1	86
368	Biosensors to monitor MS activity. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 605-608	5	4
367	Chitinase 3-like 1 is neurotoxic in primary cultured neurons. <i>Scientific Reports</i> , 2020 , 10, 7118	4.9	7

366	A Commercial Probiotic Induces Tolerogenic and Reduces Pathogenic Responses in Experimental Autoimmune Encephalomyelitis. <i>Cells</i> , 2020 , 9,	7.9	17
365	A validation study of manual atrophy measures in patients with Multiple Sclerosis. <i>Neuroradiology</i> , 2020 , 62, 955-964	3.2	4
364	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020 , 17, e1003348	11.6	13
363	Value of 3T Susceptibility-Weighted Imaging in the Diagnosis of Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1001-1008	4.4	30
362	Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study. <i>Journal of Neurology</i> , 2020 , 267, 2851-2864	5.5	4
361	Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. <i>Drug Safety</i> , 2020 , 43, 635-643	5.1	7
360	Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies. <i>Autoimmunity Reviews</i> , 2020 , 19, 102429	13.6	91
359	CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1121-1124	5	6
358	Modelling multiple sclerosis using induced pluripotent stem cells. <i>Journal of Neuroimmunology</i> , 2020 , 349, 577425	3.5	3
357	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020 , 11, 579438	4.1	5
356	Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 988-997	24.1	28
355	Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. <i>Neurology</i> , 2020 , 95, e1854-e1867	6.5	34
354	Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis. <i>Neurotherapeutics</i> , 2020 , 17, 1988-2003	6.4	4
353	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). <i>Frontiers in Neurology</i> , 2020 , 11, 632	4.1	23
352	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1163-1171	34	
351	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020 , 383, 546-557	59.2	132
350	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020 , 143, 2637-2652	11.2	22
349	Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. <i>Lancet Neurology</i> , 2020 , 19, 998-1009	24.1	38

348	Menopause and multiple sclerosis: Influence on prognosis and role of disease-modifying drugs and hormonal replacement therapy. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520952022	5	2
347	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 912-923	5	26
346	A pharmacogenetic study implicates in the response to Interferon- β in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1074-1082	5	1
345	The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MS. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1658-1669	5	18
344	NLRP3 inflammasome as prognostic factor and therapeutic target in primary progressive multiple sclerosis patients. <i>Brain</i> , 2020 , 143, 1414-1430	11.2	41
343	The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320907951 ²		1
342	Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. <i>Neurology</i> , 2020 , 94, e1950-e1960	6.5	10
341	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1009-1020	24.1	96
340	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , 2019 , 18, 1021-1033	24.1	98
339	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319871582	2	32
338	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019 , 365,	33.3	309
337	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
336	Oligoclonal bands do not represent dissemination in time in the 2017 revisions to the McDonald criteria. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1690-1691	5	5
335	Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2019 , 380, 2406-2417	59.2	111
334	The Central Vein Sign in Radiologically Isolated Syndrome. <i>American Journal of Neuroradiology</i> , 2019 , 40, 776-783	4.4	19
333	Brain regional volume estimations with NeuroQuant and FIRST: a study in patients with a clinically isolated syndrome. <i>Neuroradiology</i> , 2019 , 61, 667-674	3.2	6
332	Menarche, pregnancies, and breastfeeding do not modify long-term prognosis in multiple sclerosis. <i>Neurology</i> , 2019 , 92, e1507-e1516	6.5	31
331	Does attendance at theECTRIMS congress impact on therapeutic decisions in multiple sclerosis care?. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319835226	2	

330	Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2019 , 15, 287-300	15	79
329	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1255-1262	5	24
328	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1535-1538	5	3
327	Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis. <i>JAMA Neurology</i> , 2019 , 76, 1446-1456	17.2	59
326	Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care. <i>MDM Policy and Practice</i> , 2019 , 4, 2381468319855642	1.5	5
325	Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2019 , 18, 845-856	24.1	56
324	Head-to-head drug comparisons in multiple sclerosis: Urgent action needed. <i>Neurology</i> , 2019 , 93, 793-809	5	13
323	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. <i>Neurology</i> , 2019 , 93, e1852-e1866	6.5	22
322	Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study. <i>Journal of Medical Internet Research</i> , 2019 , 21, e14863	7.6	48
321	Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2019 , 266, 1182-1193	5.5	28
320	Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019 , 5, 2055217319887191	2	9
319	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019 , 13, 1361-1374	4.1	14
318	Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions. <i>American Journal of Pathology</i> , 2019 , 189, 665-676	5.8	13
317	Simultaneous CMV and infection following alemtuzumab treatment for multiple sclerosis. <i>Neurology</i> , 2019 , 92, 296-298	6.5	13
316	Unraveling treatment response in multiple sclerosis: A clinical and MRI challenge. <i>Neurology</i> , 2019 , 92, 180-192	6.5	50
315	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5	9
314	Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 29, 157-167	4	65
313	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 627-636	5	37

312	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 565-573	5	4
311	Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1383-1385	5	5
310	The role of the cerebellum in multiple sclerosis-150 years after Charcot. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 89, 85-98	9	31
309	The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. <i>Brain</i> , 2018 , 141, 1075-1084	11.2	64
308	Quantitative spinal cord MRI in radiologically isolated syndrome. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e436	9.1	32
307	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS - No. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 123-125	5	4
306	Classic Block Design "Pseudo"-Resting-State fMRI Changes After a Neurorehabilitation Program in Patients with Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2018 , 28, 313-319	2.8	9
305	Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. <i>Brain</i> , 2018 , 141, 1085-1093	11.2	72
304	ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. <i>European Journal of Neurology</i> , 2018 , 25, 215-237	6	96
303	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
302	Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2018 , 39, 399-404	4.4	16
301	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology, The</i> , 2018 , 17, 133-142	24.1	66
300	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology, The</i> , 2018 , 17, 162-173	24.1	2419
299	Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 346-356	5.3	13
298	Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. <i>Lancet, The</i> , 2018 , 391, 1263-1273	40	422
297	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology, The</i> , 2018 , 17, 405-415	24.1	150
296	Brain atrophy 15 years after CIS: Baseline and follow-up clinico-radiological correlations. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 721-727	5	3
295	Bone morphogenetic proteins in multiple sclerosis: Role in neuroinflammation. <i>Brain, Behavior, and Immunity</i> , 2018 , 68, 1-10	16.6	17

294	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
293	Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 301-312	5	55
292	Disability progression markers over 6-12 years in interferon-β-treated multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 322-330	5	45
291	Varicella-zoster meningovascularitis in a multiple sclerosis patient treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 358-360	5	12
290	Diagnosis of multiple sclerosis: a multicentre study to compare revised McDonald-2010 and Filippi-2010 criteria. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 316-318	5.5	14
289	Blood lymphocyte subsets identify optimal responders to IFN-β in MS. <i>Journal of Neurology</i> , 2018 , 265, 24-31	5.5	9
288	SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1485-1498	5.5	14
287	Usability of an Educational Intervention to Overcome Therapeutic Inertia in Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018 , 9, 522	4.1	2
286	Therapeutic Inertia in the New Landscape of Multiple Sclerosis Care. <i>Frontiers in Neurology</i> , 2018 , 9, 174	4.1	26
285	Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond. <i>CNS Drugs</i> , 2018 , 32, 637-651	6.7	9
284	Cladribine tablets added to IFN-β in active relapsing MS: The ONWARD study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018 , 5, e477	9.1	36
283	Myasthenia gravis following alemtuzumab therapy for multiple sclerosis. <i>Neurology</i> , 2018 , 91, 622-624	6.5	6
282	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1843-1851	5	60
281	THUR 178 Infections during grade 3/4 lymphopenia with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A23.3-A24	5.5	
280	Combined therapies to treat complex diseases: The role of the gut microbiota in multiple sclerosis. <i>Autoimmunity Reviews</i> , 2018 , 17, 165-174	13.6	55
279	NLRP3 polymorphisms and response to interferon-beta in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1507-1510	5	5
278	040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A17.1-A17	5.5	
277	Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1862-1870	5	21

276	Native ancestry is associated with optic neuritis and age of onset in hispanics with multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1362-1371	5.3	8
275	Circulating EZH2-positive T cells are decreased in multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2018 , 15, 296	10.1	5
274	Multiple sclerosis: clinical aspects. <i>Current Opinion in Neurology</i> , 2018 , 31, 752-759	7.1	135
273	Therapeutic Inertia in Multiple Sclerosis Care: A Study of Canadian Neurologists. <i>Frontiers in Neurology</i> , 2018 , 9, 781	4.1	7
272	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018 , 175, 1679-1687.e772	6.7	72
271	Exome sequencing study in patients with multiple sclerosis reveals variants associated with disease course. <i>Journal of Neuroinflammation</i> , 2018 , 15, 265	10.1	14
270	Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. <i>Annals of Neurology</i> , 2018 , 84, 527-536	9.4	21
269	Ocrelizumab: a new milestone in multiple sclerosis therapy. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418773025	6.6	65
268	044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A18.2-A19	5.5	
267	067 Efficacy of cladribine tablets in patients with highly active relapsing-remitting multiple sclerosis: analysis of pooled double-blind data from the clarity and onward studies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A27.2-A28	5.5	
266	Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain. <i>European Journal of Neurology</i> , 2018 , 25, 1189-1191	6.1	35
265	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017 , 17, 312-318	3.5	19
264	Chitinase 3-like 1 is associated with the response to interferon-beta treatment in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2017 , 303, 62-65	3.5	8
263	Treatment decisions in multiple sclerosis - insights from real-world observational studies. <i>Nature Reviews Neurology</i> , 2017 , 13, 105-118	15	126
262	Metabolomic signatures associated with disease severity in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017 , 4, e321	9.1	57
261	Ocrelizumab in Primary Progressive and Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 1694	59.2	22
260	Cumulative Dose of Macrocytic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2017 , 38, 1486-1493	4.4	7
259	Clinical and Histopathological Amelioration of Experimental Autoimmune Encephalomyelitis by AAV Vectors Expressing a Soluble Interleukin-23 Receptor. <i>Neurotherapeutics</i> , 2017 , 14, 1095-1106	6.4	6

258	Sodium intake and multiple sclerosis activity and progression in BENEFIT. <i>Annals of Neurology</i> , 2017 , 82, 20-29	9.4	50
257	Multiple Sclerosis: Epidemiologic, Clinical, and Therapeutic Aspects. <i>Neuroimaging Clinics of North America</i> , 2017 , 27, 195-204	3	32
256	Gut dysbiosis and neuroimmune responses to brain infection with Theiler's murine encephalomyelitis virus. <i>Scientific Reports</i> , 2017 , 7, 44377	4.9	29
255	Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 221-234	59.2	858
254	Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2017 , 376, 209-220	59.2	880
253	Progressive MS trials: Lessons learned. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1583-1592	5	12
252	Effect of Specific Mutations in Cd300 Complexes Formation; Potential Implication of Cd300f in Multiple Sclerosis. <i>Scientific Reports</i> , 2017 , 7, 13544	4.9	9
251	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , 2017 , 16, 797-812	24.1	243
250	Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients. <i>Neurology</i> , 2017 , 89, 1584-1593	6.5	42
249	Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , 2017 , 82, 186-195	9.4	13
248	Generation of six multiple sclerosis patient-derived induced pluripotent stem cell lines. <i>Stem Cell Research</i> , 2017 , 24, 155-159	1.6	7
247	Lesion topographies in multiple sclerosis diagnosis: A reappraisal. <i>Neurology</i> , 2017 , 89, 2351-2356	6.5	19
246	Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI. <i>European Radiology</i> , 2017 , 27, 1361-1368	8	3
245	Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2017 , 54, 4820-4831	6.2	23
244	Grey matter atrophy is associated with disability increase in natalizumab-treated patients. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 556-566	5	17
243	Measurement of Cortical Thickness and Volume of Subcortical Structures in Multiple Sclerosis: Agreement between 2D Spin-Echo and 3D MPRAGE T1-Weighted Images. <i>American Journal of Neuroradiology</i> , 2017 , 38, 250-256	4.4	6
242	Decreased soluble IFN- γ receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 937-945	5	7
241	Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education. <i>Frontiers in Neurology</i> , 2017 , 8, 430	4.1	15

240	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
239	Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. <i>International Journal of MS Care</i> , 2017 , 19, 16-24	2.3	13
238	Multiple sclerosis, and other demyelinating and autoimmune inflammatory diseases of the central nervous system. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2017 , 146, 67-84	3	18
237	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 468-75	5.5	109
236	Contribution of the symptomatic lesion in establishing MS diagnosis and prognosis. <i>Neurology</i> , 2016 , 87, 1368-74	6.5	37
235	Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study. <i>BMC Neurology</i> , 2016 , 16, 117	3.1	34
234	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016 , 92, 333-335	13.9	19
233	Increased expression of dedicator-cytokinesis-10, caspase-2 and Synaptotagmin-like 2 is associated with clinical disease activity in multiple sclerosis. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	3
232	Improved Automatic Detection of New T2 Lesions in Multiple Sclerosis Using Deformation Fields. <i>American Journal of Neuroradiology</i> , 2016 , 37, 1816-1823	4.4	17
231	Power estimation for non-standardized multisite studies. <i>NeuroImage</i> , 2016 , 134, 281-294	7.9	28
230	Assessing response to interferon- β in a multicenter dataset of patients with MS. <i>Neurology</i> , 2016 , 87, 134-40	6.5	74
229	Brain Volume Loss During the First Year of Interferon-Beta Treatment in Multiple Sclerosis: Baseline Inflammation and Regional Brain Volume Dynamics. <i>Journal of Neuroimaging</i> , 2016 , 26, 532-8	2.8	17
228	Precision medicine in multiple sclerosis: biomarkers for diagnosis, prognosis, and treatment response. <i>Current Opinion in Neurology</i> , 2016 , 29, 254-62	7.1	37
227	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , 2016 , 15, 292-303	24.1	486
226	MRI phenotypes with high neurodegeneration are associated with peripheral blood B-cell changes. <i>Human Molecular Genetics</i> , 2016 , 25, 308-16	5.6	23
225	Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2016 , 387, 1075-1084	40	271
224	An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 842-6	5	14
223	Cytokine profiles show heterogeneity of interferon- β response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e202	9.1	26

222	Differential expression of sema3A and sema7A in a murine model of multiple sclerosis: Implications for a therapeutic design. <i>Clinical Immunology</i> , 2016 , 163, 22-33	9	24
221	Protein-Based Classifier to Predict Conversion from Clinically Isolated Syndrome to Multiple Sclerosis. <i>Molecular and Cellular Proteomics</i> , 2016 , 15, 318-28	7.6	21
220	PML risk stratification using anti-JCV antibody index and L-selectin. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1048-60	5	57
219	DNA Vaccination Techniques. <i>Methods in Molecular Biology</i> , 2016 , 1304, 39-50	1.4	1
218	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67
217	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1005-15	5.5	157
216	Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 204-212	4	28
215	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. <i>G3: Genes, Genomes, Genetics</i> , 2016 , 6, 2073-9	3.2	8
214	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83
213	Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e225	9.1	94
212	Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55. <i>Journal of Immunology</i> , 2016 , 196, 4553-65	5.3	12
211	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016 , 263, 1349-60	5.5	93
210	Neurofilament light chain level is a weak risk factor for the development of MS. <i>Neurology</i> , 2016 , 87, 1076-84	6.5	61
209	Myeloid-derived suppressor cells expressing a self-antigen ameliorate experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2016 , 286, 50-60	5.7	15
208	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016 , 87, 978-87	8.5	78
207	Breast regression protein-39 is not required for experimental autoimmune encephalomyelitis induction. <i>Clinical Immunology</i> , 2015 , 160, 133-41	9	3
206	Commentary on Pique et al. paper entitled: Peripheral late reactivation of a previously typical monofocal Balo concentric sclerosis lesion. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1084-6	5	1
205	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , 2015 , 11, 471-82	15	272

204	A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis. <i>Human Molecular Genetics</i> , 2015 , 24, 5619-27	5.6	28
203	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , 2015 , 138, 918-31	11.2	103
202	Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. <i>Journal of Neuroimmunology</i> , 2015 , 278, 277-9	3.5	13
201	ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis. <i>Journal of the Neurological Sciences</i> , 2015 , 351, 174-178	3.2	60
200	Defining high, medium and low impact prognostic factors for developing multiple sclerosis. <i>Brain</i> , 2015 , 138, 1863-74	11.2	302
199	Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2015 , 12, 48	10.1	22
198	Long-term results from a phase 2 extension study of fingolimod at high and approved dose in relapsing multiple sclerosis. <i>Journal of Neurology</i> , 2015 , 262, 2627-34	5.5	15
197	Genome-wide significant association with seven novel multiple sclerosis risk loci. <i>Journal of Medical Genetics</i> , 2015 , 52, 848-55	5.8	27
196	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015 , 85, 1694-701	6.5	39
195	Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1876-8	5	1
194	Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015 , 11, 597-606	15	321
193	Molecular dynamics and intracellular signaling of the TNF-R1 with the R92Q mutation. <i>Journal of Neuroimmunology</i> , 2015 , 289, 12-20	3.5	7
192	Peripheral blood non-MAIT CD8+CD161hi cells are decreased in relapsing-remitting multiple sclerosis patients treated with interferon beta. <i>Journal of Neuroimmunology</i> , 2015 , 288, 98-101	3.5	5
191	Interferon-beta affects mitochondrial activity in CD4+ lymphocytes: Implications for mechanism of action in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1262-70	5	7
190	A new cognitive rehabilitation programme for patients with multiple sclerosis: the MS-line! ProjectO <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1344-8	5	2
189	Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE. <i>Journal of Neurology</i> , 2015 , 262, 326-36	5.5	16
188	Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e147	9.1	6
187	Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN- β <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e154	9.1	15

186	Influence of the LILRA3 Deletion on Multiple Sclerosis Risk: Original Data and Meta-Analysis. <i>PLoS ONE</i> , 2015 , 10, e0134414	3.7	4
185	Comment on severe demyelination but no astrocytopathy in clinically definite neuromyelitis optica with anti-myelin-oligodendrocyte glycoprotein antibody. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 660-1	5	
184	Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy. <i>Journal of Neurology</i> , 2015 , 262, 2617-26	5.5	28
183	A randomized, controlled, single-blind, 6-month pilot study to evaluate the efficacy of MS-Line!: a cognitive rehabilitation programme for patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1332-43	5	12
182	Should we systematically test patients with clinically isolated syndrome for auto-antibodies?. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1802-10	5	2
181	Cognitive reserve in multiple sclerosis: Protective effects of education. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1312-21	5	45
180	Predictive value of early brain atrophy on response in patients treated with interferon β . <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2015 , 2, e132	9.1	25
179	Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling. <i>NeuroImage: Clinical</i> , 2015 , 9, 640-7	5.3	19
178	Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. <i>Brain</i> , 2015 , 138, 632-43	11.2	42
177	Cell-specific effects in different immune subsets associated with SOCS1 genotypes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1498-512	5	8
176	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015 , 77, 447-57	9.4	43
175	NLRP3 inflammasome is associated with the response to IFN- β in patients with multiple sclerosis. <i>Brain</i> , 2015 , 138, 644-52	11.2	75
174	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014 , 20, 272-82	50.5	103
173	Pregnancy, sex and hormonal factors in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 527-36	5	52
172	Early predictors of multiple sclerosis after a typical clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1721-6	5	28
171	Activation-induced cell death in T lymphocytes from multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2014 , 272, 51-5	3.5	8
170	Multiple sclerosis in 2013: novel triggers, treatment targets and brain atrophy measures. <i>Nature Reviews Neurology</i> , 2014 , 10, 72-3	15	2
169	Vitamin D as an early predictor of multiple sclerosis activity and progression. <i>JAMA Neurology</i> , 2014 , 71, 306-14	17.2	312

168	Body fluid biomarkers in multiple sclerosis. <i>Lancet Neurology, The</i> , 2014 , 13, 113-26	24.1	157
167	Comment on: Prevalence of brain magnetic resonance imaging meeting Barkhof and McDonald criteria for dissemination in space among headache patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 897-8	5	
166	HLA alleles as biomarkers of high-titre neutralising antibodies to interferon- β therapy in multiple sclerosis. <i>Journal of Medical Genetics</i> , 2014 , 51, 395-400	5.8	17
165	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , 2014 , 1, 605-17	5.3	39
164	Up-regulation of inducible heat shock protein-70 expression in multiple sclerosis patients. <i>Autoimmunity</i> , 2014 , 47, 127-33	3	14
163	Diagnosis and trials of clinically isolated syndrome. <i>Lancet Neurology, The</i> , 2014 , 13, 962-3	24.1	3
162	Nerve conduction velocity is regulated by the inositol polyphosphate-4-phosphatase II gene. <i>American Journal of Pathology</i> , 2014 , 184, 2420-9	5.8	5
161	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1471-7	5	22
160	Natalizumab: risk stratification of individual patients with multiple sclerosis. <i>CNS Drugs</i> , 2014 , 28, 641-8	6.7	21
159	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
158	No association of IFI16 (interferon-inducible protein 16) variants with susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 49-52	3.5	1
157	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. <i>Lancet Neurology, The</i> , 2014 , 13, 472-81	24.1	77
156	Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. <i>Annals of Neurology</i> , 2014 , 76, 231-40	9.4	42
155	Radiologically isolated syndrome: 5-year risk for an initial clinical event. <i>PLoS ONE</i> , 2014 , 9, e90509	3.7	190
154	Myeloid-derived suppressor cells are generated during retroviral transduction of murine bone marrow. <i>Cell Transplantation</i> , 2014 , 23, 73-85	4	9
153	Secondary progression is not the only explanation. <i>Acta Medica Portuguesa</i> , 2014 , 27, 393-6	1.4	3
152	MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. <i>Neurology</i> , 2014 , 82, 1491-8	6.5	141
151	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 234-42	5	17

150	Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014 , 1, e47	9.1	8
149	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 851-8	5.5	84
148	Ancient and recent selective pressures shaped genetic diversity at AIM2-like nucleic acid sensors. <i>Genome Biology and Evolution</i> , 2014 , 6, 830-45	3.9	22
147	N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 2338-43	5.5	42
146	Validation of semaphorin 7A and ala-His-dipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2014 , 11, 181	10.1	22
145	Comment on Fingolimod to treat severe MS after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Maillart et al. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 510-1	5	
144	Evaluating the response to glatiramer acetate in relapsing-remitting multiple sclerosis (RRMS) patients. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1602-8	5	33
143	Regulatory lymphocytes are key factors in MHC-independent resistance to EAE. <i>Journal of Immunology Research</i> , 2014 , 2014, 156380	4.5	3
142	NMO spectrum disorders: how wide is the spectrum?. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1417-9	5	2
141	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. <i>Journal of Neuroinflammation</i> , 2014 , 11, 46	10.1	63
140	Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 271, 56-9	3.5	6
139	Hsp70 regulates immune response in experimental autoimmune encephalomyelitis. <i>PLoS ONE</i> , 2014 , 9, e105737	3.7	30
138	Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. <i>Journal of Neurology</i> , 2013 , 260, 2016-22	5.5	47
137	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013 , 260, 2023-32	5.5	72
136	Treatment of cognitive impairment in multiple sclerosis: position paper. <i>Journal of Neurology</i> , 2013 , 260, 1452-68	5.5	161
135	TNFRSF1A polymorphisms rs1800693 and rs4149584 in patients with multiple sclerosis. <i>Neurology</i> , 2013 , 80, 2010-6	6.5	19
134	Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis. <i>Trends in Molecular Medicine</i> , 2013 , 19, 157-64	11.5	35
133	Inhibition of delta-like ligand 4 decreases Th1/Th17 response in a mouse model of multiple sclerosis. <i>Neuroscience Letters</i> , 2013 , 541, 161-6	3.3	17

132	Analysis of prognostic factors associated with longitudinally extensive transverse myelitis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 742-8	5	28
131	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 1082-91	5.5	209
130	Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1175-81	5	75
129	Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1074-83	5	72
128	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. <i>Brain</i> , 2013 , 136, 1778-82	11.2	47
127	Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2013 , 381, 2167-75	40	236
126	Circulating levels of soluble apoptosis-related molecules in patients with multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2013 , 263, 152-4	3.5	11
125	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology, The</i> , 2013 , 12, 756-67	24.1	163
124	Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis. <i>Journal of Medical Genetics</i> , 2013 , 50, 25-33	5.8	45
123	Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. <i>Journal of Medical Genetics</i> , 2013 , 50, 140-3	5.8	29
122	CSF oligoclonal bands are important in the diagnosis of multiple sclerosis, unreasonably downplayed by the McDonald criteria 2010: No. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 717-8	5	5
121	Serum biomarker gMS-Classifer2: predicting conversion to clinically definite multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e59953	3.7	3
120	Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-beta. <i>PLoS ONE</i> , 2013 , 8, e60994	3.7	23
119	Risk acceptance in multiple sclerosis patients on natalizumab treatment. <i>PLoS ONE</i> , 2013 , 8, e82796	3.7	21
118	Multiple sclerosis: more pieces of the immunological puzzle. <i>Lancet Neurology, The</i> , 2012 , 11, 9-10	24.1	8
117	Finategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology, The</i> , 2012 , 11, 131-9	24.1	60
116	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 143-52	5	186
115	Treatment with MOG-DNA vaccines induces CD4+CD25+FoxP3+ regulatory T cells and up-regulates genes with neuroprotective functions in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2012 , 9, 139	10.1	31

114	Heat shock protein 70: roles in multiple sclerosis. <i>Molecular Medicine</i> , 2012 , 18, 1018-28	6.2	44
113	Placebo-controlled trial of oral laquinimod for multiple sclerosis. <i>New England Journal of Medicine</i> , 2012 , 366, 1000-9	59.2	290
112	Natalizumab discontinuation after PML risk stratification: outcome from a shared and informed decision. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1193-6	5	19
111	DNA-based vaccines for multiple sclerosis: current status and future directions. <i>Clinical Immunology</i> , 2012 , 142, 76-83	9	29
110	Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation. <i>Clinical Immunology</i> , 2012 , 142, 84-92	9	22
109	Replication study of 10 genes showing evidence for association with multiple sclerosis: validation of TMEM39A, IL12B and CBLB [correction of CLBL] genes. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 959-65	5	24
108	Olfactory dysfunction in multiple sclerosis: association with secondary progression. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 616-21	5	45
107	Subcutaneous alemtuzumab for multiple sclerosis. <i>Expert Review of Clinical Immunology</i> , 2012 , 8, 423-6	5.1	2
106	EBV-specific immune responses in patients with multiple sclerosis responding to IFN β therapy. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 605-9	5	15
105	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1466-71	5	47
104	THC and CBD oromucosal spray (Sativex $\text{\textsuperscript{\textcircled{R}}}$) in the management of spasticity associated with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 627-37	4.3	67
103	Review of methodological issues of clinical trials in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311 Suppl 1, S35-42	3.2	11
102	Multiple sclerosis: current treatment algorithms. <i>Current Opinion in Neurology</i> , 2011 , 24, 230-7	7.1	47
101	Tumor necrosis factor alpha (TNF- α) anti-TNF- α and demyelination revisited: an ongoing story. <i>Journal of Neuroimmunology</i> , 2011 , 234, 1-6	3.5	94
100	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , 2011 , 10, 520-9	24.1	178
99	Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011 , 69, 292-302	9.4	6480
98	Implication of the Toll-like receptor 4 pathway in the response to interferon- β in multiple sclerosis. <i>Annals of Neurology</i> , 2011 , 70, 634-45	9.4	33
97	New insights in the pathophysiology and treatment of multiple sclerosis spasticity and related symptoms. Foreword. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 1	4.3	1

96	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
95	Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. <i>Brain</i> , 2011 , 134, 693-703	11.2	76
94	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 319-26	5	8
93	Principles of a new treatment algorithm in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 351-62	4.3	20
92	Interferon β for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. <i>Archives of Neurology</i> , 2011 , 68, 1421-7		34
91	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. <i>Nature Reviews Neurology</i> , 2011 , 8, 13-21	15	57
90	Search for specific biomarkers of IFN β bioactivity in patients with multiple sclerosis. <i>PLoS ONE</i> , 2011 , 6, e23634	3.7	40
89	Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 402-15	59.2	1686
88	Targeting dendritic cells to treat multiple sclerosis. <i>Nature Reviews Neurology</i> , 2010 , 6, 499-507	15	48
87	Fingolimod for relapsing multiple sclerosis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1183-96	4	18
86	Gender-associated differences of perforin polymorphisms in the susceptibility to multiple sclerosis. <i>Journal of Immunology</i> , 2010 , 185, 5392-404	5.3	23
85	Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. <i>Brain</i> , 2010 , 133, 1082-93	11.2	197
84	Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 67, 159-69	9.4	145
83	Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. <i>Lancet Neurology</i> , 2010 , 9, 381-90	24.1	261
82	B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS. <i>Journal of Neuroimmunology</i> , 2010 , 223, 135-7	3.5	5
81	Orchestrating innate immune responses in multiple sclerosis: molecular players. <i>Journal of Neuroimmunology</i> , 2010 , 225, 5-12	3.5	19
80	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 68, 409-11	9.4	35
79	Predicting responders to therapies for multiple sclerosis. <i>Nature Reviews Neurology</i> , 2009 , 5, 553-60	15	101

78	A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 587-92		96
77	Tolerance induction in experimental autoimmune encephalomyelitis using non-myeloablative hematopoietic gene therapy with autoantigen. <i>Molecular Therapy</i> , 2009 , 17, 897-905	11.7	26
76	Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. <i>Archives of Neurology</i> , 2009 , 66, 1345-52		28
75	Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. <i>Archives of Neurology</i> , 2009 , 66, 972-8		94
74	Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 1303-10	5	50
73	Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. <i>Clinical Immunology</i> , 2009 , 130, 145-50	9	36
72	Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS. <i>Clinical Immunology</i> , 2009 , 133, 364-74	9	14
71	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology</i> , 2009 , 8, 987-97	24.1	279
70	Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. <i>Human Brain Mapping</i> , 2009 , 30, 2412-25	5.9	47
69	Early treatment: PreCISe-ly what the patient needs. <i>Journal of the Neurological Sciences</i> , 2009 , 287 Suppl 1, S2-6	3.2	2
68	Multiple sclerosis therapy: historical and future perspectives. <i>Current Opinion in Neurology</i> , 2009 , 22, S1-S3	7.1	
67	Immunotherapy for neurological diseases. <i>Clinical Immunology</i> , 2008 , 128, 294-305	9	42
66	FTY720 (fingolimod) for relapsing multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2008 , 8, 699-714	4.3	33
65	Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis. <i>Archives of Neurology</i> , 2008 , 65, 337-44		135
64	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 455-64	5	46
63	Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 412-4	5	5
62	mtDNA nt13708A variant increases the risk of multiple sclerosis. <i>PLoS ONE</i> , 2008 , 3, e1530	3.7	55
61	Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008 , 255, 480-7	5.5	58

60	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , 2008 , 255, 683-91	5.5	65
59	Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. <i>Annals of Neurology</i> , 2008 , 63, 790-3	9.4	83
58	Will Rogers phenomenon in multiple sclerosis. <i>Annals of Neurology</i> , 2008 , 64, 428-33	9.4	66
57	Identification of a novel risk locus for multiple sclerosis at 13q31.3 by a pooled genome-wide scan of 500,000 single nucleotide polymorphisms. <i>PLoS ONE</i> , 2008 , 3, e3490	3.7	83
56	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. <i>Journal of International Medical Research</i> , 2008 , 36, 204-8; author reply 208-10	1.4	2
55	Lack of association between antimyelin antibodies and progression to multiple sclerosis. <i>New England Journal of Medicine</i> , 2007 , 356, 371-8	59.2	197
54	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology</i> , 2007 , 6, 677-86	24.1	246
53	Interferon beta in secondary progressive multiple sclerosis : daily clinical practice. <i>Journal of Neurology</i> , 2007 , 254, 849-53	5.5	4
52	Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results. <i>Archives of Neurology</i> , 2007 , 64, 1292-8		41
51	Antimyelin antibodies with no progression to multiple sclerosis. <i>New England Journal of Medicine</i> , 2007 , 356, 426-8	59.2	45
50	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet</i> , 2007 , 370, 389-97	40	417
49	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. <i>Lancet Neurology</i> , 2006 , 5, 221-7	24.1	94
48	MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". <i>Lancet Neurology</i> , 2006 , 5, 841-52	24.1	194
47	Altered maturation of circulating dendritic cells in primary progressive MS patients. <i>Journal of Neuroimmunology</i> , 2006 , 175, 183-91	3.5	32
46	Deficient Fas expression by CD4+ CCR5+ T cells in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006 , 180, 147-58	3.5	14
45	Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. <i>Annals of Neurology</i> , 2006 , 59, 344-52	9.4	260
44	Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. <i>Human Molecular Genetics</i> , 2006 , 15, 2813-24	5.6	246
43	Fatigue in progressive multiple sclerosis is associated with low levels of dehydroepiandrosterone. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 487-94	5	51

42	Oral fingolimod (FTY720) for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2006 , 355, 1124-40	59.2	877
41	The value of animal models for drug development in multiple sclerosis. <i>Brain</i> , 2006 , 129, 1940-52	11.2	118
40	TNF-alpha converting enzyme (TACE) protein expression in different clinical subtypes of multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, 701-6	5.5	14
39	The importance of long-term data in multiple sclerosis. <i>Journal of Neurology</i> , 2006 , 253, vi9-vi15	5.5	10
38	Association Cluster Detector: a tool for heuristic detection of significance clusters in whole-genome scans. <i>Bioinformatics</i> , 2005 , 21 Suppl 2, ii180-1	7.2	3
37	Transcription-based prediction of response to IFNbeta using supervised computational methods. <i>PLoS Biology</i> , 2005 , 3, e2	9.7	122
36	Primary progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2005 , 18, 261-6	7.1	27
35	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. <i>Lancet Neurology</i> , 2005 , 4, 281-8	24.1	436
34	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. <i>Lancet Neurology</i> , 2005 , 4, 341-8	24.1	112
33	Plasma osteopontin levels in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 158, 231-9	3.5	143
32	Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2005 , 164, 140-7	3.5	21
31	Is optic neuritis more benign than other first attacks in multiple sclerosis?. <i>Annals of Neurology</i> , 2005 , 57, 210-5	9.4	93
30	Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. <i>Journal of Neurology</i> , 2005 , 252, 795-800	5.5	52
29	Interferon-beta 1b in the treatment of multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 2877-86	4	12
28	Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 306-9	5	167
27	Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 618-20	5	7
26	Overview of European pilot study of interferon b-1b in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, S62-S64	5	20
25	Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 413-6	5	22

24	Clinical characteristics of responders to interferon therapy for relapsing MS. <i>Neurology</i> , 2004 , 62, 1653; author reply 1653	6.5	25
23	Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. <i>Archives of Neurology</i> , 2004 , 61, 222-4		27
22	The pros and cons of early treatment of relapsing forms of multiple sclerosis. <i>Journal of Neurology</i> , 2004 , 251 Suppl 4, IV30-4	5.5	4
21	Overview of European pilot study of interferon beta-1b in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004 , 10 Suppl 1, S62; discussion 62-4	5	7
20	Unconventional therapy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2003 , 9, 320-2	5	15
19	Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange. <i>Journal of Neurology</i> , 2003 , 250, 243-4	5.5	4
18	A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease. <i>Journal of Neuroimmunology</i> , 2003 , 143, 124-8	3.5	33
17	Serial immunoprecipitation assays for interferon- γ (IFN)-beta antibodies in multiple sclerosis patients. <i>European Cytokine Network</i> , 2003 , 14, 154-7	3.3	8
16	The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. <i>Journal of Neuroimmunology</i> , 2002 , 130, 194-201	3.5	68
15	Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. <i>Annals of Neurology</i> , 2002 , 52, 400-6	9.4	89
14	Serial proton spectroscopy, magnetization transfer ratio and T 2 relaxation in pseudotumoral demyelinating lesions. <i>NMR in Biomedicine</i> , 2002 , 15, 284-92	4.4	11
13	Reversible white matter alterations in encephalopathy associated with autoimmune thyroid disease. <i>Journal of Neurology</i> , 2002 , 249, 1063-5	5.5	32
12	Interferon-gamma regulates oxidative stress during experimental autoimmune encephalomyelitis. <i>Experimental Neurology</i> , 2002 , 177, 21-31	5.7	21
11	Specific proliferation towards myelin antigens in patients with multiple sclerosis during a relapse. <i>Autoimmunity</i> , 2002 , 35, 45-50	3	17
10	The proteasome is a major autoantigen in multiple sclerosis. <i>Brain</i> , 2002 , 125, 2658-67	11.2	38
9	Serial diffusion-weighted MR imaging and proton MR spectroscopy of acute large demyelinating brain lesions: case report. <i>American Journal of Neuroradiology</i> , 2002 , 23, 989-94	4.4	48
8	Anticardiolipin antibodies are not a useful screening tool in a nonselected large group of patients with multiple sclerosis. <i>Annals of Neurology</i> , 2001 , 49, 408-411	9.4	30
7	Altered inflammatory response and increased neurodegeneration in metallothionein I+II deficient mice during experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2001 , 119, 248-60	3.5	66

6	Frequency of multiple sclerosis in Menorca, Balearic islands, Spain. <i>Neuroepidemiology</i> , 2001 , 20, 129-33	5.4	22
5	Treatment with anti-interferon-gamma monoclonal antibodies modifies experimental autoimmune encephalomyelitis in interferon-gamma receptor knockout mice. <i>Experimental Neurology</i> , 2001 , 172, 460-8	5.7	26
4	Proton magnetic resonance spectroscopy in primary and secondary progressive multiple sclerosis. <i>NMR in Biomedicine</i> , 2000 , 13, 57-63	4.4	36
3	CD4(+)CD45RO(+)CD49d(high) cells are involved in the pathogenesis of relapsing-remitting multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2000 , 111, 215-23	3.5	15
2	Gangliosides do not elicit experimental autoimmune encephalomyelitis in Lewis rats and SJL mice. <i>Journal of Neuroimmunology</i> , 1998 , 84, 24-9	3.5	8
1	Daclizumab to treat multiple sclerosis399-404		